Navigation Links
TriZetto, Sanovia Join Forces to Offer First Integrated Platform That Helps Payers Control Pharmacy Costs
Date:1/12/2009

Platform Integrates Medical and Pharmacy Data to Drive Real-Time Pharmacy Utilization Management Decisions

NEWPORT BEACH, Calif. and PHILADELPHIA, Jan. 12 /PRNewswire/ -- The TriZetto Group, Inc. and Sanovia Corporation today announced a definitive partnership agreement to offer the market's first platform that integrates real-time medical data with pharmacy data to automate prior-authorizations of medications and help plans manage pharmacy expenditures.

TriZetto's Facets(R) and QNXT(TM) core administration systems will integrate with PA-Logic(TM), Sanovia's automated pharmacy utilization management application, to confirm member eligibility, benefit design and formulary status and apply best-practice clinical guidelines to evaluate provider requests for select medications. The integrated data platform enables Integrated Healthcare Management and will be available to TriZetto customers in mid-2009.

"In combining the access of real-time medical claims data with Sanovia's pharmacy utilization management application, this integrated system will use built-in intelligence to drive automation, standardization and consistency in the evaluation of pharmaceuticals," said Marty Mattei, Pharm.D., TriZetto's director of pharmacy solutions. "The result will be a more efficient workflow process that helps reduce administrative costs associated with managing the pharmacy benefit. Additionally, because the Integrated Healthcare Management platform enables more efficient collaboration between the payer, provider and member, it will enhance quality of care and help reduce clinical costs by optimizing therapeutic regimens, thereby helping ensure the appropriate use of pharmaceuticals."

"Health plans seek a better way to manage the utilization of expensive specialty pharmaceuticals," said Jerry Osband, M.D., TriZetto's chief medical officer. "Pharmacy staff at payer organizations today must access dat
'/>"/>

SOURCE Sanovia Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Jeff Timmons and the Heather Trew Foundation Join Forces to Promote Organ Donations
2. Cheryl Burke of Dancing with the Stars Joins Forces With Time Life To Create a Brand New Dance Workout, DISCO ABS
3. Burnham and HeadNorth Foundation join forces to advance spinal cord research
4. Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations
5. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
6. Top Athletes Join Forces for a New Mission: Athlete-Engineered Skincare to Support Performance and Benefit Charity
7. Sonic Innovations Presents Donation to the Armed Forces Foundation
8. Hydron Technologies, Inc. and Brand Builders International, LLC Join Forces to Form New Entity
9. SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) Adult Day Centers
10. LodgeNet and Control4 Join Forces to Deliver Ultimate Personalized Guest Experience With One Touch Control
11. Informed-Choice Reinforces Need to Test Supplements for Inadvertent Contamination After Recent NFL Players Positive Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... This report studies the global ... forecast period of 2014 to 2019. This market ... 6.5% from 2014 to 2019. , Further Inquiry ... the global pharmacovigilance and drug safety software market ... basis of functionality, namely, adverse event reporting software, ...
(Date:3/30/2015)... On March 19th, 2015, in the ... the Detroit Lions, LiveToBeSober.org hosted the “Fighting Addiction Together” ... and bishops as well as other civic leaders and ... the luncheon, including retired Detroit Lions wide receiver Herman ... two survivors of their own personal battles with addiction, ...
(Date:3/30/2015)... Dr. Shahdad Arami is now ... receive $200 off their Invisalign treatment. Many people crave ... a mouthful of metal. Invisalign offers an alternative. According ... is effective for straightening teeth but has no aesthetic ... oral appearance. The Invisalign system allows both teenagers and ...
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition ... current Epax® Ultra and Core concentrates manufactured in ... certification ensures the manufacturing process and all physical ... regulations for Halal. , The new Halal ... further advance its customer service to a global ...
(Date:3/30/2015)... Los Angeles, CA (PRWEB) March 30, 2015 ... its traditional blue polo for yellow to inspire courage ... who suffers from Severe Combined Immunodeficiency (SCID). SCID causes ... a bone marrow transplant is needed to allow the ... his second transplant last Friday, created a video with ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2
... HRAL) announced that it has received additional licenses from,Wal-Mart ... WMT ), to open their ninth and tenth ... #3195 located at 1070 Major,Mackenzie Drive in Richmond Hill ... Y006A in Markham will both officially open today. This,expansion ...
... ... 2008 Guidance Amedisys to Host ... Amedisys, Inc.,(Nasdaq: AMED ) ("Amedisys" or "the Company"), one of America,s ... September 30, 2007: Three-Month Periods Ended September 30, 2007 and 2006, ...
... Pieris AG,(Munich, Germany) and Pepscan ... of a research collaboration aimed at ... (GPCRs) and their,development as therapeutic candidates. ... next generation targeted,therapeutics with clear advantages ...
... Oct. 30 CryoLife, Inc. (NYSE: CRY ),a ... Scott B. Capps has been named vice president, clinical ... vice president and,general manager of CryoLife Europa, Ltd., based ... CryoLife in 1995 and has held several positions with,the ...
... at launch, due to its First To File ... ... owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL has received tentative ... 40 mg,80 mg, 160 mg and 320 mg. Total annual market sales for ...
... to Mouth Guards, GLENDALE, Calif., Oct. 23 ... to pay as much attention to,you oral health as ... concerned about their total health, weight issues and,being healthy, ... health of,their mouth," said Jean Honny, president of the ...
Cached Medicine News:Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 2Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 4Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 5Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 6Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 7Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 8Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 9Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 10Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 11Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 12Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 13Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 14Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 15Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 2Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 3Health News:CryoLife Announces Additions to Management Team 2Health News:Ranbaxy Receives Tentative Approval For Valsartan Tablets 2Health News:California Dental Hygienists Offer Health Tips for Weekend Warriors & Fitness Buffs 2
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
(Date:3/29/2015)... TITUSVILLE, N.J. , March 29, 2015 /PRNewswire/ ... delayed time to relapse compared to placebo in ... 3 clinical study published this week in the ... (JAMA) Psychiatry . Results of ... recent New Drug Application (NDA) filing for three-month ...
(Date:3/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... the issuance of an aggregate of 30,000 stock options ... aggregate of 120,500 stock options to employees and consultants ... three years and will be exercisable for a period ... per stock option. About Covalon Covalon ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
... , PRINCETON, N.J. and SAN DIEGO, ... biotechnology company committed to research and product discovery for ... announced results from an in vitro study evaluating TBR-652 ... tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the ...
... PARIS and TARRYTOWN, N.Y., Sept. 11 Sanofi-aventis ... Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced the ... Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line ... by an Independent Data Monitoring Committee (IDMC). As part ...
Cached Medicine Technology:Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 3Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 5
Implex cemented hip stem....
Stability cemented stem....
Porous foundation 440 series....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: